AngioDynamics (NASDAQ:ANGO) Rating Reiterated by HC Wainwright

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, MarketBeat Ratings reports. They currently have a $14.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s price target points to a potential upside of 129.51% from the stock’s previous close. HC Wainwright also issued estimates for AngioDynamics’ FY2026 earnings at ($0.26) EPS.

Separately, Canaccord Genuity Group cut their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday.

AngioDynamics Price Performance

ANGO opened at $6.10 on Friday. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The company’s 50 day moving average price is $7.48 and its two-hundred day moving average price is $6.63. The firm has a market capitalization of $244.34 million, a price-to-earnings ratio of -1.26 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. AngioDynamics’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. As a group, equities research analysts predict that AngioDynamics will post -0.41 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of AngioDynamics during the 3rd quarter valued at about $103,000. Quarry LP lifted its stake in AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 2,594 shares during the period. Systematic Financial Management LP boosted its holdings in shares of AngioDynamics by 8.4% during the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock worth $12,763,000 after buying an additional 162,972 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $80,000. Finally, Millennium Management LLC increased its stake in shares of AngioDynamics by 41.9% in the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after acquiring an additional 529,861 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.